[1]
Sashihara, T.; Sueki, N.; Furuichi, K.; Ikegami, S. Effect of growth conditions of Lactobacillus gasseri OLL2809 on the immunostimulatory activity for production of interleukin-12 (p70) by murine splenocytes. Int. J. Food Microbiol., 2007, 120(3), 274-281.
[2]
van Baarlen, P.; Troost, F.J.; van Hemert, S.; van der Meer, C.; de Vos, W.M.; de Groot, P.J.; Hooiveld, G.J.; Brummer, R.J.; Kleerebezem, M. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc. Natl. Acad. Sci. USA, 2009, 106(7), 2371-2376.
[3]
Jankovic, I.; Sybesma, W.; Phothirath, P.; Ananta, E.; Mercenier, A. Application of probiotics in food products-challenges and new approaches. Curr. Opin. Biotechnol., 2010, 21(2), 175-181.
[4]
Sanders, M.E.; Klaenhammer, T.R.; Ouwehand, A.C.; Pot, B.; Johansen, E.; Heimbach, J.T.; Marco, M.L.; Tennilä, J.; Ross, R.P.; Franz, C.; Pagé, N.; Pridmore, R.D.; Leyer, G.; Salminen, S.; Charbonneau, D.; Call, E.; Lenoir-Wijnkoop, I. Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics. Ann. N. Y. Acad. Sci., 2014, 1309, 1-18.
[5]
Zacarías, M.F.; Souza, T.C.; Zaburlín, N. Influence of technological treatments on the functionality of bifidobacterium lactis INL1, a breast milk-derived probiotic. J. Food Sci., 2017, 82(10), 2462-2470.
[6]
Toshimitsu, T.; Ozaki, S.; Mochizuki, J.; Furuichi, K.; Asami, Y. Effects of Lactobacillus plantarum strain OLL2712 culture conditions on the anti-inflammatory activities for murine immune cells and obese and type 2 diabetic mice. Appl. Environ. Microbiol., 2017, 83(7), e03001-e03016.
[7]
Gionchetti, P.; Rizzello, F.; Venturi, A.; Brigidi, P.; Matteuzzi, D.; Bazzocchi, G.; Poggioli, G.; Miglioli, M.; Campieri, M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology, 2000, 119(2), 305-309.
[8]
Gionchetti, P.; Rizzello, F.; Helwig, U.; Venturi, A.; Lammers, K.M.; Brigidi, P.; Vitali, B.; Poggioli, G.; Miglioli, M.; Campieri, M. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology, 2003, 124(5), 1202-1209.
[9]
Shen, J.; Zuo, Z.X.; Mao, A.P. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: Meta-analysis of randomized controlled trials. Inflamm. Bowel Dis., 2014, 20(1), 21-35.
[10]
Cinque, B.; La Torre, C.; Lombardi, F.; Palumbo, P.; Van der Rest, M.; Cifone, M.G. Production conditions affect the in vitro anti-tumoral effects of a high concentration multi-strain probiotic preparation. PLoS One, 2016, 11(9), e0163216.
[11]
Cinque, B.; La Torre, C.; Lombardi, F.; Palumbo, P.; Evtoski, Z.; Jr Santini, S.; Falone, S.; Cimini, A.; Amicarelli, F.; Cifone, M.G. VSL#3 probiotic differently influences IEC-6 intestinal epithelial cell status and function. J. Cell. Physiol., 2017, 232(12), 3530-3539.
[12]
Biagioli, M.; Laghi, L.; Carino, A.; Cipriani, S.; Distrutti, E.; Marchianò, S.; Parolin, C.; Scarpelli, P.; Vitali, B.; Fiorucci, S. Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity. Front. Pharmacol., 2017, 8, 505.
[13]
Trinchieri, V.; Laghi, L.; Vitali, B. Efficacy and safety of a multistrain probiotic formulation depends from manufacturing. Front. Immunol., 2017, 8, 1474.
[14]
Sambuy, Y.; De Angelis, I.; Ranaldi, G.; Scarino, M.L.; Stammati, A.; Zucco, F. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol., 2005, 21(1), 1-26.
[15]
Varasteh, S.; Fink-Gremmels, J.; Garssen, J.; Braber, S. α-Lipoic acid prevents the intestinal epithelial monolayer damage under heat stress conditions: Model experiments in Caco-2 cells. Eur. J. Nutr., 2018, 57(4), 1577-1589.
[16]
Zhang, J.; Lu, Y.; Wei, J.; Li, L.; Han, L. Protective effect of carboxytmethylpachymaran on TNF-α-induced damage in Caco-2 cell monolayers. Int. J. Biol. Macromol., 2016, 93(Pt A), 506-511,
[17]
Anderson, R.C.; Cookson, A.L.; McNabb, W.C.; Kelly, W.J.; Roy, N.C. Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. FEMS Microbiol. Lett., 2010, 309(2), 184-192.
[18]
Morini, J.; Babini, G.; Barbieri, S.; Baiocco, G.; Ottolenghi, A. The interplay between radioresistant Caco-2 cells and the immune system increases epithelial layer permeability and alters signaling protein spectrum. Front. Immunol., 2017, 8, 223.
[19]
Primavera, R.; Palumbo, P.; Celia, C.; Cinque, B.; Carata, E.; Carafa, M.; Paolino, D.; Cifone, M.G.; Di Marzio, L. An insight of in vitro transport of PEGylated non-ionic surfactant vesicles (NSVs) across the intestinal polarized enterocyte monolayers. Eur. J. Pharm. Biopharm., 2018, 127, 432-442.
[20]
Xiao, G.; Tang, L.; Yuan, F. Eicosapentaenoic acid enhances heat stress-impaired intestinal epithelial barrier function in Caco-2 cells. PLoS One, 2013, 8(9), e73571.
[21]
Grześkowiak, Ł.; Isolauri, E.; Salminen, S.; Gueimonde, M. Manufacturing process influences properties of probiotic bacteria. Br. J. Nutr., 2010, 105, 887-894.
[22]
Clements, M.L.; Levine, M.M.; Ristaino, P.A.; Daya, V.E.; Hughes, T.P. Exogenous lactobacilli fed to man – their fate and ability to prevent diarrheal disease. Prog. Food Nutr. Sci., 1983, 7, 29-37.
[23]
Lipinska, L.; Klewicki, R.; Elżbieta, K.; Kolodziejczyk, K.; Sójka, M.; Nowak, A. Antifungal activity of Lactobacillus sp. bacteria in the presence of xylitol and galactosyl-xylitol. BioMed Res. Int., 2016, 1-8.
[24]
Otte, J.M.; Podolsky, D.K. Functional modulation of enterocytes by grampositive and gram-negative microorganisms. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286(4), G613-G626.
[25]
Dai, C.; Zhao, D.H.; Jiang, M. VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int. J. Mol. Med., 2012, 29(2), 202-208.
[26]
Krishnan, M.; Penrose, H.M.; Shah, N.N.; Marchelletta, R.R.; McCole, D.F. VSL#3 probiotic stimulates T-cell protein tyrosine phosphatase–mediated recovery of IFN-γ–induced intestinal epithelial barrier defects. Inflamm. Bowel Dis., 2016, 22(12), 2811-2823.
[27]
Shibolet, O.; Karmeli, F.; Eliakim, R.; Swennen, E.; Brigidi, P.; Gionchetti, P.; Campieri, M.; Morgenstern, S.; Rachmilewitz, D. Variable response to probiotics in two models of experimental colitis in rats. Inflamm. Bowel Dis., 2002, 8(6), 399-406.
[28]
Di Giacinto, C.; Marinaro, M.; Sanchez, M.; Strober, W.; Boirivant, M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J. Immunol., 2005, 174(6), 3237-3246.
[29]
Mennigen, R.; Nolte, K.; Rijcken, E.; Utech, M.; Loeffler, B.; Senninger, N.; Bruewer, M. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296(5), G1140-G1149.
[30]
Kumar, M.; Kissoon-Singh, V.; Coria, A.L.; Moreau, F.; Chadee, K. Probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2017, 312(1), G34-G45.
[31]
Chelakkot, C.; Ghim, J.; Ryu, S.H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp. Mol. Med., 2018, 50(8), 103.
[32]
Allain, T.; Amat, C.B.; Motta, J.P.; Manko, A.; Buret, A.G. Interactions of Giardia sp. with the intestinal barrier: Epithelium, mucus, and microbiota. Tissue Barriers, 2017, 5(1), e1274354.
[33]
Halpern, M.D.; Denning, P.W. The role of intestinal epithelial barrier function in the development of NEC. Tissue Barriers, 2015, 3(1-2), e1000707.
[34]
Moore, S.A.; Nighot, P.; Reyes, C.; Rawat, M.; McKee, J.; Lemon, D.; Hanson, J.; Ma, T.Y. Intestinal barrier dysfunction in human necrotizing enterocolitis. J. Pediatr. Surg., 2016, 51(12), 1907-1913.
[35]
Douillard, F.P.; Mora, D.; Eijlander, R.T.; Wels, M.; de Vos, W.M. Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3. PLoS One, 2018, 13(2), e0192452.
[36]
Kolaček, S.; Hojsak, I.; Berni Canani, R.; Guarino, A.; Indrio, F.; Orel, R.; Pot, B.; Shamir, R.; Szajewska, H.; Vandenplas, Y.; van Goudoever, J.; Weizman, Z. ESPGHAN working group for probiotics and prebiotics. Commercial probiotic products: A call for improved quality control. A Position Paper by the ESPGHAN working group for probiotics and prebiotics. J. Pediatr. Gastroenterol. Nutr., 2017, 65(1), 117-124.
57
5